Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
8,518 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
Kumar S, Jacobus S, Cohen A, Weiss M, Callander N, Singh A, Parker T, Green M, Thertulien R, Parsons B, Kumar P, Kapoor P, Rosenberg A, Dib E, Almquist D, Zonder J, Faber E, Wei Z, Anderson K, Lonial S, Richardson P, Orlowski R, Wagner L, Rajkumar SV. · N Engl J Med · 2026 · cited 3 timesOpen accessclinical trial, phase iii, comparative study
- Outcomes of stereotactic radiosurgery for spine multiple myeloma-a systematic review.
Izhar M, Hori YS, Kattaa AH, Park DJ, Chang SD. · Neurosurg Rev · 2026 · cited 0 timessystematic review
- Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis.
Lv T, Liu M, Zhang W, Zhang J, Fang Y. · Front Cardiovasc Med · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Physiological prehabilitation for patients undergoing cellular therapy in multiple myeloma and lymphoma: a systematic review.
Barredo JMS, Lim CC, Loy Y, Ooi M, Zeng Y. · Support Care Cancer · 2026 · cited 0 timessystematic review
- Unveiling the Prognostic Power of Circulating Tumor DNA in Multiple Myeloma: A Systematic Review and Updated Meta-Analysis.
Ying W, Fan L, Li R, Qu X. · Cancer Med · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
Mailankody S, Mitra S, Herrera K, Ziccheddu B, Cadzin B, Eren OC, Farzana T, Ullah T, Landa J, Derkach A, Chaudhari J, McAvoy DP, Hosszu K, Shah GL, Landau H, Maura F, Dogan A, Giralt S, Wang X, Sadelain M, Smith EL, Brentjens RJ, Leslie C, Usmani SZ, Perica K. · Blood · 2026 · cited 1 timesclinical trial, phase i
- Progressive multifocal leukoencephalopathy, bispecific antibodies, and multiple myeloma: a case report and systematic review of the literature.
Tzanni M, Polyzoidis P, Angelopoulos K, Skafida A, Moustaka I, Sepsa A, Korkolopoulou P, Velonakis G, Stavrinou LC, Voulgarelis M, Stergiou I, Fotiou D. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study.
Goren E, Sexton R, Orlowski RZ, Hoering A. · Trials · 2026 · cited 0 timesOpen accessclinical trial, phase iii, letter
- Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Miller KC, Fei T, Faustino Ramos RJ, Castro F, Gradissimo A, Block T, Hamadeh I, Maclachlan KH, Hultcrantz ML, Hassoun H, Mailankody S, Rajeeve S, Maura F, Merz M, Hashmi H, Firestone R, Jurgens E, Shah GL, Scordo M, Landau HJ, Giralt SA, Korde N, Pianko MJ, Usmani SZ, Peled JU, Shah UA, Lesokhin AM. · Clin Cancer Res · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
- Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial.
Nadeem O, Cordas Dos Santos DM, Magidson S, Matous J, Medvedova E, O'Donnell E, Redd RA, Liu Y, Midha S, Sperling AS, Arters F, Davie C, Ricciardi C, Toenges R, Bidikian N, Hussein S, Alberge JB, Kim S, Pantano-Rubino L, Corrado F, Ashton H, Addonizio D, Mohamed S, Sturtevant A, Marto M, Bergeron A, Malfona F, Panaro K, Richardson PG, Ritz J, Trippa L, Ghobrial IM. · Nat Med · 2026 · cited 2 timesOpen accessclinical trial, phase ii, randomized controlled trial
- Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Su L, Ye M, Peng B, Fan L, Wu J. · Front Immunol · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
Merz M, Souto Filho JT, Voorhees PM, Einsele H, Schjesvold F, Cliff ERS, Mateos MV, Hungria V, Cohen YC, de Larrea CF, Beksac M, Landgren O, Usmani SZ, Costa LJ, Gagelmann N. · J Hematol Oncol · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Teclistamab and daratumumab immune-based doublet therapy for relapsed/refractory multiple myeloma: the TRIMM-2 study.
Rodríguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk NWCJ, Chari A, Dholaria B, Kortüm KM, Mateos MV, McKay JT, Rosiñol L, Balari AS, Wäsch R, Bhutani M, Weisel K, Bahlis N, Vishwamitra D, Skerget S, Bakshi K, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A. · Blood Adv · 2026 · cited 0 timesmulticenter study, clinical trial, phase i
- Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegård M, Wang D, Pei L, Wroblewski S, Ariës IM, Quijano Cardé NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O, MajesTEC-9 Trial Investigators. · N Engl J Med · 2026 · cited 7 timesclinical trial, phase iii, comparative study
- Early intervention for high-risk smoldering multiple myeloma (SMM).
Chen PH, Jhou HJ, Ho CL, Huang HL, Lee CH. · Cochrane Database Syst Rev · 2026 · cited 0 timesmeta-analysis, systematic review
- Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.
Kumar S, Knopf B, Asmus E, Gertz M, Kapoor P, Hayman S, Roy V, Fonder A, Christenson L, Hobbs M, Bergsagel L, Fonseca R, Dingli D, Dispenzieri A, Gonsalves W, Kourelis T, Sher T, Siddiqi M, Warsame R, Ailawadhi S, Rajkumar SV, Buadi F. · Clin Lymphoma Myeloma Leuk · 2026 · cited 1 timesclinical trial, phase ii
- Efficacy and Safety of Prophylactic Tocilizumab in Patients with Multiple Myeloma Receiving Bispecific Antibodies: A Systematic Review and Meta-Analysis.
Tancherla A, Dharmaraja F, Kurniawan A. · Oncol Res Treat · 2026 · cited 0 timesmeta-analysis, systematic review
- Elevated D-dimer levels in high-risk multiple myeloma patients: a systematic review and meta-analysis.
Sun C, Guo Y, Zhao W. · Front Oncol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.
Xu J, Liu L, Xie W, Su L, Wang W, Li C, Liu Q, Kang Y, Zhang Y, Luo W, Huang Z, Zhang C, Sun C, Hu Y, Mei H. · Nat Med · 2026 · cited 1 timesOpen accessclinical trial, phase i
- Multiple Myeloma in Children and Young Adults: A Systematic Literature Review.
Poultsaki G, Vassilakopoulos TP, Terpos E, Papadakis V. · Clin Exp Med · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.
Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ. · Blood Adv · 2026 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Pseudohyperphosphatemia in Multiple Myeloma: A Systematic Review of Case Reports and Case Series.
Dabir M, Mousavi MK, Mohamadi M, Maleki A. · J Clin Lab Anal · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.
Schaefers C, Khandanpour C, Hänel M, Kull M, Alsdorf W, Kamili A, Kosch R, Krüger W, Bohl S, Mai EK, Scheid C, Einsele H, Brüggemann M, Suling A, Zapf A, Bokemeyer C, Weisel K, Leypoldt L. · BMC Cancer · 2026 · cited 0 timesOpen accessclinical trial protocol
- Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.
Facon T, Kumar SK, Orlowski RZ, Bahlis N, Moreau P, Goldschmidt H, Basu S, Hulin C, Zweegman S, Weisel K, Perrot A, Jacquet C, Raje N, Manier S, Chari A, Hansson M, Mohty M, Delforge M, Plesner T, Cook G, Leleu X, Quach H, Venner CP, Tiab M, Macro M, Frenzel L, Wang G, Pei H, Bolyard K, Carson R, Borgsten F, Usmani SZ. · Leukemia · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003).
Xiao F, Wang L, Li F, Wang F, Zhong Y, Qu X, Chang C, Li Z, Liu Y, Dou X, Wen L, Peng N, Lu J, Hou J. · Med · 2026 · cited 0 timesclinical trial, phase ii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.